Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | PPM1B | O75688 | 1/20 | 0.42 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.42 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.42 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.42 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14404536 | 1.00 | NPC1 (0.46) | NPC1PPM1BLGALS9LGALS1LGALS3 | |
| SCHEMBL4287430 | 1.00 | NPC1 (0.46) | NPC1PPM1BLGALS9LGALS1LGALS3 | |
| SCHEMBL23895298 | 0.88 | NPC1 (0.46) | NPC1PPM1BMEN1KMT2ALMNA | |
| SCHEMBL14404534 | 0.86 | NPC1 (0.46) | NPC1PPM1BMEN1KMT2ALMNA | |
| SCHEMBL8583044 | 0.85 | NPC1 (0.45) | NPC1PPM1BMEN1KMT2ALMNA | |
| SCHEMBL1521266 | 0.84 | NPC1 (0.46) | NPC1PPM1BMEN1KMT2ALMNA | |
| SCHEMBL1521263 | 0.84 | NPC1 (0.46) | NPC1PPM1BMEN1KMT2ALMNA | |
| SCHEMBL1521261 | 0.84 | NPC1 (0.46) | NPC1PPM1BMEN1KMT2ALMNA | |
| SCHEMBL14404532 | 0.84 | NPC1 (0.46) | NPC1PPM1BMEN1KMT2ALMNA | |
| SCHEMBL8669182 | 0.83 | NPC1 (0.46) | NPC1PPM1BPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137499-A1 | BENZYLPHENYL GLUCOPYRANOSIDE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-05-28 | — | — | US | disclosed |
| EP-2048150-A1 | BENZYL PHENYL GLUCOPYRANOSIDE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2009-04-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137499-A1 | BENZYLPHENYL GLUCOPYRANOSIDE DERIVATIVE | SLC5A1, SLC5A2, SLC2A1 | NPC1 153/4885PPM1B 3001/4885LGALS9 969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.